77 research outputs found
Radiation-Induced Leiomyosarcoma: Does Antimetabolite Chemotherapy Contribute? A Report of Three Cases
Purpose: Radiation therapy in low and high doses is known to be associated with the occurrence of late secondary sarcomas.
The addition of chemotherapy has not been clearly demonstrated as a contributing factor. We describe three patients with
radiation-associated leiomyosarcoma who had also received antimetabolite chemotherapy
Phase I/II Archaeological Testing on Fleet Street (18AP111), Cornhill Street (18AP112), and 26 Market Space (18AP109), for the Proposed Fleet and Cornhill Streets Reconstruction Project, Annapolis, Maryland, 2008
From 3/31/08 to 5/30/08 staff from the Department of Anthropology, University of Maryland, College Park (UMCP), Archaeology in Annapolis Project, conducted archaeological testing on city-owned public right-of-ways at 26 Market Space (18AP109), on Fleet Street (18AP111), and on Cornhill Street (18AP112) prior to the upcoming undergrounding and replacement of city-owned utilities along and beneath these streets. In addition, from 06/02/08 to 06/20/08, undergraduate and graduate students enrolled in the University of Maryland, Field School in Urban Archaeology conducted further testing of city-owned public right-of-ways on Cornhill Street (18AP112). This Phase II investigation has been conducted at the request of the City of Annapolis, Department of Public Works (DPW) as part of the Fleet and Cornhill Streets Reconstruction Project. The project area comprises the streetscapes of what is referred to as the Fleet-Cornhill neighborhood. Eleven test units were used to evaluate archaeological integrity and significance of these sites and to evaluate the potential effects of planned construction on archaeological resources.
Background research shows that the Fleet Street neighborhood was initially developed in the late 17th and early 18th century. Throughout the later 18th, 19th and 20th centuries the area became known as an ethnically diverse working class neighborhood in the heart of the city. Historical residents of the project area have included in the early 20th century native people of European, African descent, and a community of Russian Ashkenazi Jews in the early 20th century. Previous archaeological investigations found evidence of intact archaeological resources within the project area dating from the 18th to 20th centuries.
In addition to providing evidence of patterns of Annapolis’ historical urbanization, several features excavated in the course of this project have shed light on the development of public space within this working class neighborhood. These features include a corduroy or log road dating to the first quarter of the 18th century; what is believed to be a Yoruba ritual bundle dating to the first quarter of the 18th century; and a series of city improvements (i.e. curbs, sidewalks, and a public well) dating from the 18th through 20th centuries.
A high degree of archaeological integrity at all three sites has the potential to add considerable knowledge concerning both Annapolis city development, and an ethnically diverse working class community.
All three sites are eligible for inclusion in the National Register of Historic Places under Criterion D. Because of the integrity and uniqueness of the archaeological record within the project area, it is recommended that further archaeological research be done. Included within this recommendation is the need to process flotation and macrobotanical samples recovered in the fiel
Velocity Field Statistics in Star-Forming Regions. I. Centroid Velocity Observations
The probability density functions (pdfs) of molecular line centroid velocity
fluctuations and fluctuation differences at different spatial lags are
estimated for several nearby molecular clouds with active internal star
formation. The data consist of over 75,000 CO line profiles divided
among twelve spatially and/or kinematically distinct regions. Although three
regions (all in Mon R2) appear nearly Gaussian, the others show strong evidence
for non-Gaussian, often nearly exponential, centroid velocity pdfs, possibly
with power law contributions in the far tails. Evidence for nearly exponential
centroid pdfs in the neutral HI component of the ISM is also presented, based
on older optical and radio observations. These results are in contrast to pdfs
found in isotropic incompressible turbulence experiments and simulations.
Furthermore, no evidence is found for the scaling of difference pdf kurtosis
with Reynolds number which is seen in incompressible turbulence, and the
spatial distribution of high-amplitude velocity differences shows little
indication of the filamentary appearance predicted by decay simulations
dominated by vortical interactions. The variation with lag of the difference
pdf moments is presented as a constraint on future simulations.Comment: LaTeX, 23 pages, with 15 Figures included separately as gif image
files. Refereed/revised version accepted to the Astrophysical Journal. A
complete (but much larger) postscript version is available from
http://ktaadn.gsfc.nasa.gov/~miesc
Antibodies Produced by CLL Phenotype B Cells in Patients With Myasthenia Gravis Are Not Directed Against Neuromuscular Endplates
BACKGROUND AND OBJECTIVES
Myasthenia gravis (MG) can in rare cases be an autoimmune phenomenon associated with hematologic malignancies such as chronic lymphocytic leukemia (CLL). It is unclear whether in patients with MG and CLL, the leukemic B cells are the ones directly driving the autoimmune response against neuromuscular endplates.
METHODS
We identified patients with acetylcholine receptor antibody-positive (AChR) MG and CLL or monoclonal B-cell lymphocytosis (MBL), a precursor to CLL, and described their clinical features, including treatment responses. We generated recombinant monoclonal antibodies (mAbs) corresponding to the B-cell receptors of the CLL phenotype B cells and screened them for autoantigen binding.
RESULTS
A computational immune cell screen revealed a subgroup of 5/38 patients with MG and 0/21 healthy controls who displayed a CLL-like B-cell phenotype. In follow-up hematologic flow cytometry, 2 of these 5 patients were diagnosed with an MBL. An additional patient with AChR MG as a complication of manifest CLL presented at our neuromuscular clinic and was successfully treated with the anti-CD20 therapy obinutuzumab plus chlorambucil. We investigated the specificities of expanding CLL-like B-cell clones to assess a direct causal link between the 2 diseases. However, we observed no reactivity of the clones against the AChR, antigens at the neuromuscular junction, or other common autoantigens.
DISCUSSION
Our study suggests that AChR autoantibodies are produced by nonmalignant, polyclonal B cells The new anti-CD20 treatment obinutuzumab might be considered in effectively treating AChR MG.
CLASSIFICATION OF EVIDENCE
This is a single case study and provides Class IV evidence that obinutuzumab is safe to use in patients with MG
Effectiveness of moving on: an Australian designed generic self-management program for people with a chronic illness
Background: This paper presents the evaluation of “Moving On”, a generic self-management program for people with a chronic illness developed by Arthritis NSW. The program aims to help participants identify their need for behavior change and acquire the knowledge and skills to implement changes that promote their health and quality of life.
Method: A prospective pragmatic randomised controlled trial involving two group programs in community settings: the intervention program (Moving On) and a control program (light physical activity). Participants were recruited by primary health care providers across the north-west region of metropolitan Sydney, Australia between June 2009 and October 2010. Patient outcomes were self-reported via pre- and post-program surveys completed at the time of enrolment and sixteen weeks after program commencement. Primary outcomes were change in self-efficacy (Self-efficacy for Managing Chronic Disease 6-Item Scale), self-management knowledge and behaviour and perceived health status (Self-Rated Health Scale and the Health Distress Scale).
Results: A total of 388 patient referrals were received, of whom 250 (64.4%) enrolled in the study. Three patients withdrew prior to allocation. 25 block randomisations were performed by a statistician external to the research team: 123 patients were allocated to the intervention program and 124 were allocated to the control program. 97 (78.9%) of the intervention participants commenced their program. The overall attrition rate of 40.5% included withdrawals from the study and both programs. 24.4% of participants withdrew from the intervention program but not the study and 22.6% withdrew from the control program but not the study. A total of 62 patients completed the intervention program and follow-up evaluation survey and 77 patients completed the control program and follow- up evaluation survey.
At 16 weeks follow-up there was no significant difference between intervention and control groups in self-efficacy; however, there was an increase in self-efficacy from baseline to follow-up for the intervention participants (t=−1.948, p=0.028). There were no significant differences in self-rated health or health distress scores between groups at follow-up, with both groups reporting a significant decrease in health distress scores. There was no significant difference between or within groups in self-management knowledge and stage of change of behaviours at follow-up. Intervention group attenders had significantly higher physical activity (t=−4.053, p=0.000) and nutrition scores (t=2.315, p= 0.01) at follow-up; however, these did not remain significant after adjustment for covariates.
At follow-up, significantly more participants in the control group (20.8%) indicated that they did not have a self-management plan compared to those in the intervention group (8.8%) (X2=4.671, p=0.031). There were no significant changes in other self-management knowledge areas and behaviours after adjusting for covariates at follow-up.
Conclusions: The study produced mixed findings. Differences between groups as allocated were diluted by the high proportion of patients not completing the program. Further monitoring and evaluation are needed of the impact and cost effectiveness of the program.
Trial registration: Australian New Zealand Clinical Trials Registry: ACTRN1260900029821
Recommended from our members
A randomised controlled trial of positive memory training for the treatment of depression within schizophrenia
Abstract
Background: Depression is highly prevalent within individuals diagnosed with schizophrenia, and is associated with an increased risk of suicide. There are no current evidence based treatments for low mood within this group. The specific targeting of co-morbid conditions within complex mental health problems lends itself to the development of short-term structured interventions which are relatively easy to disseminate within health services. A brief cognitive intervention based on a competitive memory theory of depression, is being evaluated in terms of its effectiveness in reducing depression within this group.
Methods/Design: This is a single blind, intention-to-treat, multi-site, randomized controlled trial comparing Positive Memory Training plus Treatment as Usual with Treatment as Usual alone. Participants will be recruited from two NHS Trusts in Southern England. In order to be eligible, participants must have a DSM-V diagnosis of schizophrenia or schizo-affective disorder and exhibit at least a mild level of depression. Following baseline assessment eligible participants will be randomly allocated to either the Positive Memory Training plus Treatment as Usual group or the Treatment as Usual group. Outcome will be assessed at the end of treatment (3-months) and at 6-month and 9-month post randomization by assessors blind to group allocation. The primary outcome will be levels of depression and secondary outcomes will be severity of psychotic symptoms and cost-effectiveness. Semi-structured interviews will be conducted with all participants who are allocated to the treatment group so as to explore the acceptability of the intervention.
Discussion: Cognitive behaviour therapy is recommended for individuals diagnosed with schizophrenia. However, the number of sessions and length of training required to deliver this intervention has caused a limit in availability. The current trial will evaluate a short-term structured protocol which targets a co-morbid condition often considered of primary importance by service users. If successful the intervention will be an important addition to current initiatives aimed at increasing access to psychological therapies for people diagnosed with severe mental health problems.
Trial registration: Current Controlled Trials. ISRCTN99485756. Registered 13 March 2014
Evaluation of a system of structured, pro-active care for chronic depression in primary care: a randomised controlled trial
Background: People with chronic depression are frequently lost from effective care, with resulting psychological, physical and social morbidity and considerable social and financial societal costs. This randomised controlled trial will evaluate whether regular structured practice nurse reviews lead to better mental health and social outcomes for these patients and will assess the cost-effectiveness of the structured reviews compared to usual care. The hypothesis is that structured, pro-active care of patients with chronic depression in primary care will lead to a cost-effective improvement in medical and social outcomes when compared with usual general practitioner (GP) care.Methods/Design: Participants were recruited from 42 general practices throughout the United Kingdom. Eligible participants had to have a history of chronic major depression, recurrent major depression or chronic dsythymia confirmed using the Composite International Diagnostic Interview (CIDI). They also needed to score 14 or above on the Beck Depression Inventory (BDI-II) at recruitment.Once consented, participants were randomised to treatment as usual from their general practice (controls) or the practice nurse led intervention. The intervention includes a specially prepared education booklet and a comprehensive baseline assessment of participants' mood and any associated physical and psycho-social factors, followed by regular 3 monthly reviews by the nurse over the 2 year study period. At these appointments intervention participants' mood will be reviewed, together with their current pharmacological and psychological treatments and any relevant social factors, with the nurse suggesting possible amendments according to evidence based guidelines. This is a chronic disease management model, similar to that used for other long-term conditions in primary care. The primary outcome is the BDI-II, measured at baseline and 6 monthly by self-complete postal questionnaire. Secondary outcomes collected by self-complete questionnaire at baseline and 2 years include social functioning, quality of life and data for the economic analyses. Health service data will be collected from GP notes for the 24 months before recruitment and the 24 months of the study.Discussion: 558 participants were recruited, 282 to the intervention and 276 to the control arm. The majority were recruited via practice database searches using relevant READ codes
High prevalence of mismatch repair deficiency in prostate cancers diagnosed in mismatch repair gene mutation carriers from the colon cancer family registry
The question of whether prostate cancer is part of the Lynch syndrome spectrum of tumors is unresolved. We investigated the mismatch repair (MMR) status and pathologic features of prostate cancers diagnosed in MMR gene mutation carriers. Prostate cancers (mean age at diagnosis = 62 ± SD = 8 years) from 32 MMR mutation carriers (23 MSH2, 5 MLH1 and 4 MSH6) enrolled in the Australasian, Mayo Clinic and Ontario sites of the Colon Cancer Family Registry were examined for clinico-pathologic features and MMR-deficiency (immunohistochemical loss of MMR protein expression and high levels of microsatellite instability; MSI-H). Tumor MMR-deficiency was observed for 22 cases [69 %; 95 % confidence interval (CI) 50–83 %], with the highest prevalence of MMR-deficiency in tumors from MSH2 mutation carriers (19/23, 83 %) compared with MLH1 and MSH6 carriers combined (3/9, 33 %; p = 0.01). MMR-deficient tumors had increased levels of tumor infiltrating lymphocytes compared with tumors without MMR-deficiency (p = 0.04). Under the assumption that tumour MMR-deficiency occurred only because the cancer was caused by the germline mutation, mutation carriers are at 3.2-fold (95 % CI 2.0–6.3) increased risk of prostate cancer, and when assessed by gene, the relative risk was greatest for MSH2 carriers (5.8, 95 % CI 2.6–20.9). Prostate cancer was the first or only diagnosed tumor in 37 % of carriers. MMR gene mutation carriers have at least a twofold or greater increased risk of developing MMR-deficient prostate cancer where the risk is highest for MSH2 mutation carriers. MMR IHC screening of prostate cancers will aid in identifying MMR gene mutation carriers
The IMPROVE guidelines (Ischaemia Models: Procedural Refinements Of in Vivo Experiments)
Most in vivo models of ischaemic stroke target the middle cerebral artery and a spectrum of stroke severities, from mild to substantial, can be achieved. This review describes opportunities to improve the in vivo modelling of ischaemic stroke and animal welfare. It provides a number of recommendations to minimise the level of severity in the most common rodent models of middle cerebral artery occlusion, while sustaining or improving the scientific outcomes. The recommendations cover basic requirements pre-surgery, selecting the most appropriate anaesthetic and analgesic regimen, as well as intraoperative and post-operative care. The aim is to provide support for researchers and animal care staff to refine their procedures and practices, and implement small incremental changes to improve the welfare of the animals used and to answer the scientific question under investigation. All recommendations are recapitulated in a summary poster (see supplementary information)
The theoretical and practical determination of clinical cut-offs for the British Sign Language versions of PHQ-9 and GAD-7
- …